Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 2, 2009, Pages

  George, Isaac ^a   Morrow, Brad ^a   Xu, Kai ^a   Yi, Geng Hua ^a   Holmes, Jeffrey ^b   Wu, Ed X ^c   Li, Zhihe ^d   Protter, Andrew A ^d   Oz, Mehmet C ^a   Wang, Jie ^a,e  

^a College of Physicians and Surgeons of Columbia University ^*  (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d SCIOS INC   (United States)

^e EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Heart failure; Myocardial function

Indexed keywords

BLOOD CLOTTING FACTOR 8; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; CYCLOOXYGENASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY COMPLIANCE; ARTERY EMBOLISM; ARTICLE; COMPLIANCE (PHYSICAL); CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DOG; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; GEOMETRY; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFUSION PUMP; MALE; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SYSTOLE;

ANIMALS; CYCLIC GMP; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOGS; ECHOCARDIOGRAPHY; EMBOLISM; FACTOR VIII; FEMALE; FIBROSIS; HEART FAILURE; INFUSION PUMPS; MACROPHAGES; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; STROKE VOLUME; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 68049102295     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00661.2008     Document Type: Article

References (44)

1. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4: 37-44, 1998. (Pubitemid 28252539)
2. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 90: 435-438, 2002. (Pubitemid 34895071)
3. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J 152: 1084-1090, 2006.
4. Burkhoff D, Sagawa K. Ventricular efficiency predicted by an analytical model. Am J Physiol Regul Integr Comp Physiol 250: R1021-R1027, 1986. (Pubitemid 16065634)
5. Cameron VA, Rademaker MT, Ellmers LJ, Espiner EA, Nicholls G, Richards AM. Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology 141: 4690-4697, 2000.
6. Cao L, Garner D. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 25: 227-234, 1995.
7. Chen HH, Grantham A, Schirger JA, Jougasaki M, Redfield MM, Burnett JC. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 36: 1706-1712, 2000. (Pubitemid 30826011)
8. Cheng Y, George I, Yi GH, Reiken S, Gu A, Tao YK, Muraskin J, Qin S, He KL, Hay I, Yu K, Oz MC, Burkhoff D, Holmes J, Wang J. Bradycardic therapy improves left ventricular function and remodeling in dogs with coronary embolization-induced chronic heart failure. J Pharmacol Exp Ther 321: 469-476, 2007. (Pubitemid 46624487)
9. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343: 246-253, 2000. (Pubitemid 30490392)
10. Costa MD, Bosc LV, Majowicz MP, Vidal NA, Balaszczuk AM, Arranz CT. Atrial natriuretic peptide modifies arterial blood pressure through nitric oxide pathways in rats. Hypertension 35: 1119-1123, 2000.
11. Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT. Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res 22: 686-695, 1988. (Pubitemid 18248480)
12. ATP channel opening. Am J Physiol Heart Circ Physiol 284: H1592-H1600, 2003.
13. Feldman DS, Ikonomidis JS, Uber WE, Van Bakel AB, Pereira NL, Crumbley AJ 3rd, Tann SM. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 10: 292-296, 2004.
14. Gordon GR, Schumann R, Rastegar H, Khabbaz K, England MR. Nesiritide for treatment of perioperative low cardiac output syndromes in cardiac surgical patients: an initial experience. J Anesth 20: 307-311, 2006. (Pubitemid 44650714)
15. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, Horie H, Ohnishi M, Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37: 1820-1826, 2001.
16. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 76: 91-96, 1993. (Pubitemid 23027559)
17. Hosoda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, Shirakami G, Suga S, Ogawa Y, Yasue H, Imura H. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension 17: 1152-1155, 1991.
18. Houben AJ, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 19: 411-419, 2005.
19. Jugdutt BI, Khan MI. Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction. Circulation 89: 2297-2307, 1994. (Pubitemid 24142811)
20. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts. Circ Res 94: 453-461, 2004.
21. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 49: 667-674, 2007. (Pubitemid 46205046)
22. Knecht M, Burkhoff D, Yi GH, Popiskis S, Homma S, Packer M, Wang J. Coronary endothelial dysfunction precedes heart failure and reduction of coronary reserve in awake dogs. J Mol Cell Cardiol 29: 217-227, 1997. (Pubitemid 27129145)
23. + channels in cultured vascular smooth muscle cells. Circ Res 74: 471-476, 1994.
24. Lainchbury JG, Richards AM, Nicholls MG, Espiner EA, Yandle TG. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocrinol Metab 84: 723-739, 1999.
25. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 339: 321-328, 1998.
26. MacDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91: 2043-2048, 1995.
27. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, Heitjan DF, Katz SD. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94: 3184-3189, 1996. (Pubitemid 26427485)
28. Mentzer RM, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Luber JM Jr, Smedira NG, NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 49: 716-726, 2007.
29. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 107: 2697-2701, 2003. (Pubitemid 36667243)
30. Moro C, Berlan M. Cardiovascular and metabolic effects of natriuretic peptides. Fundam Clin Pharmacol 20: 41-49, 2006.
31. Munger MA. Management of acute decompensated heart failure: treatment, controversy, and future directions. Pharmacotherapy 26: 131S-138S, 2006.
32. Nakamura M, Arakawa N, Yoshida H, Makita S, Niinuma H, Hiramori K. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J 135: 414-420, 1998. (Pubitemid 28125676)
33. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure. JAMA 287: 1531-1540, 2002.
34. Ren Y, Shen Y, Shao H, Qian J, Wu H, Jing H. Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats. Clin Chim Acta 377: 83-87, 2007. (Pubitemid 44908233)
35. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol Heart Circ Physiol 260: H1379-H1384, 1991.
36. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111: 1487-1491, 2005.
37. Salzberg SP, Filsoufi F, Anyanwu A, Harbou KV, Gass A, Pinney SP, Carpentier A, Adams DH. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 80: 502-506, 2005. (Pubitemid 41019468)
38. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39: 798-803, 1997. (Pubitemid 34185326)
39. Suga H, Goto Y, Futaki S, Kawaguchi O, Yaku H, Hata K, Takasago T. Systolic pressure-volume area (PVA) as the energy of contraction in Starling's law of the heart. Heart Vessels 6: 65-70, 1991.
40. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97: 4239-4244, 2000. (Pubitemid 30226117)
41. Tokudome T, Horio T, Soeki T, Mori K, Kishimoto I, Suga S, Yoshihara F, Kawano Y, Kohno M, Kangawa K. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-2 signaling pathways. Endocrinology 145: 2131-2140, 2004. (Pubitemid 38535041)
42. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91: 1127-1134, 2002. (Pubitemid 36076361)
43. Van der Zander K, Houben AJHM, Hofstra L, Kroon AA, de Leeuw PW. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 285: H1206-H1212, 2003. (Pubitemid 37048178)
44. Yoshimura M, Yasue M, Morita E, Sakaino N, Jougasaki Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84: 1581-1588, 1991.